血浆基因分型技术在小细胞肺癌中的应用:实用综述
转移性非小细胞肺癌(NSCLC)的合理治疗取决于及时检测可靶向的基因组改变。高灵敏度基因分型技术促进了血浆基因分型检测的发展,可在不依赖传统组织基因分型的情况下无创检测血浆游离DNA中的可靶向改变。仅少数平台具备与组织基因分型参考标准对比的前瞻性验证数据,经过验证的检测具有高特异性和阳性预测值,但敏感性有限。
要点
- 血浆基因分型可无创检测血浆游离DNA中的可靶向基因组改变
- 仅少数平台具备与组织基因分型参考标准对比的前瞻性验证数据
- 经过验证的血浆基因分型检测具有高特异性和阳性预测值,敏感性较有限
核心结论
- 经过验证的血浆基因分型检测在检测到可靶向基因组改变或检测到替代性非靶向驱动突变并可推断前者不存在时,可考虑用于临床决策。
研究设计与样本
- 本文为实用综述,总结血浆基因分型技术在小细胞肺癌中的应用,未报告系统检索范围。
主要发现
- 高灵敏度基因分型技术促进了血浆基因分型检测的发展,可在不依赖传统组织基因分型的情况下无创检测血浆游离DNA中的可靶向改变。
- 血浆基因分型检测平台的快速增加导致肿瘤学家对各项检测的特征、局限性及临床适用场景存在困惑。
- 仅少数平台具备与组织基因分型参考标准对比的前瞻性验证数据。
- 利用临床试验中采集的配对组织和血浆标本对替代平台进行仔细的回顾性验证,是一种替代但可靠的验证策略。
- 经过良好验证的血浆基因分型检测一致表现为高特异性和阳性预测值,敏感性较有限。
临床怎么用
- 目前,经过验证的检测可在检测到可靶向基因组改变或检测到替代性非靶向驱动突变并可推断前者不存在时,可考虑用于临床决策。
局限性
- 仅少数平台具备与组织基因分型参考标准对比的前瞻性验证数据。
- 经过良好验证的血浆基因分型检测敏感性较有限。
- 血浆基因分型检测平台的快速增加导致肿瘤学家对各项检测的特征、局限性及临床适用场景存在困惑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rational treatment of metastatic NSCLC hinges on the timely detection of potentially targetable genomic alterations to guide therapy. Recent advances in highly sensitive genotyping technologies have allowed for development of novel plasma genotyping assays that are capable of noninvasively detecting targetable alterations in plasma cell-free DNA without reliance on traditional tissue genotyping. The rapid development of plasma genotyping has led to an explosion in the number of assay platforms available from both commercial and laboratory sources. The sheer number of such platforms has led to confusion among oncologists as to both the test characteristics and limitations of individual plasma genotyping assays and the clinical context in which these tests may be utilized either alone or in combination with traditional tissue genotyping. Reliable data from prospective validation against a tissue genotyping reference standard are available for only a limited number of platforms. Careful retrospective validation of alternative platforms utilizing paired tissue and plasma specimens collected under the auspices of clinical trials represent an alternative but reliable validation strategy. A consistent trend among these well-validated plasma genotyping assays has been the observation of high specificity and positive predictive value and more limited sensitivity. At present, validated assays can be considered actionable in instances in which a targetable genomic alteration is detected or an alternative nontargetable driver mutation is detected and can be used to infer the absence of one of the former.
引用
- Sacher AG, Komatsubara KM, Oxnard GR, et al. Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review. J Thorac Oncol. 2017. PMID: 28611011. doi:10.1016/j.jtho.2017.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。